$ANIK
Anika Therapeutics, Inc. Stock $anik

$anik Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-K Financial Statement

#000117184317001121 Filed on February 24, 2017

Income Statement

Concept	2015 Q4	2015 Q3	2015 Q2
Revenue	$30.89M	$23.68M	$22.90M
YoY Change	32.85%	7.37%	-12.83%
Cost Of Revenue	$6.290M	$5.176M	$5.274M
YoY Change	14.14%	-9.59%	-1.11%
Gross Profit	$19.32M	$18.50M	$17.62M
YoY Change	56.17%	13.85%	10.61%
Gross Profit Margin	62.53%	78.12%	76.95%
Selling, General & Admin	$4.520M	$3.309M	$3.388M
YoY Change	23.16%	-18.19%	-12.36%
% of Gross Profit	23.4%	17.89%	19.22%
Research & Development	$3.020M	$2.061M	$1.812M
YoY Change	52.53%	3.06%	-3.26%
% of Gross Profit	15.63%	11.14%	10.28%
Depreciation & Amortization	$980.0K	$970.0K	$920.0K
YoY Change	-13.27%	-19.83%	-21.37%
% of Gross Profit	5.07%	5.24%	5.22%
Operating Expenses	$7.540M	$5.370M	$5.200M
YoY Change	33.22%	-11.16%	-9.39%
Operating Profit	$11.78M	$13.14M	$12.43M
YoY Change	75.54%	27.7%	-18.24%
Interest Expense	$40.00K	$34.00K	$24.00K
YoY Change	0.0%	242.16%	304.38%
% of Operating Profit	0.34%	0.26%	0.19%
Other Income/Expense, Net
YoY Change
Pretax Income	$17.10M	$13.17M	$12.45M
YoY Change	40.97%	27.9%	-18.12%
Income Tax	$6.060M	$4.789M	$4.634M
% Of Pretax Income	35.44%	36.37%	37.21%
Net Earnings	$11.04M	$8.380M	$7.820M
YoY Change	41.27%	35.8%	-15.93%
Net Earnings / Revenue	35.74%	35.39%	34.14%
Basic Earnings Per Share	$0.74	$0.56	$0.52
Diluted Earnings Per Share	$0.72	$0.55	$0.51
COMMON SHARES
Basic Shares Outstanding		14.97M	14.96M
Diluted Shares Outstanding	15.35M	15.32M	15.34M

Balance Sheet

Concept	2015 Q4	2015 Q3	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$138.5M	$130.5M	$122.4M
YoY Change	29.56%	42.16%	44.17%
Cash & Equivalents	$110.7M	$108.5M	$103.9M
Short-Term Investments	$27.80M	$22.00M	$18.50M
Other Short-Term Assets	$1.400M	$2.300M	$2.400M
YoY Change	-46.15%	-28.13%	50.0%
Inventory	$14.94M	$12.08M	$11.72M
Prepaid Expenses
Receivables	$21.65M	$23.38M	$19.17M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$176.4M	$168.3M	$155.7M
YoY Change	28.0%	30.76%	30.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$40.11M	$33.80M	$31.52M
YoY Change	26.65%	5.62%	-2.71%
Goodwill	$7.482M	$7.713M	$7.611M
YoY Change	-10.28%
Intangibles	$11.66M	$12.99M	$13.08M
YoY Change	-21.75%
Long-Term Investments
YoY Change
Other Assets	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$59.32M	$54.57M	$52.29M
YoY Change	7.9%	-3.93%	-12.27%
TOTAL ASSETS
Total Short-Term Assets	$176.4M	$168.3M	$155.7M
Total Long-Term Assets	$59.32M	$54.57M	$52.29M
Total Assets	$235.7M	$222.9M	$208.0M
YoY Change	22.27%	20.14%	16.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.302M	$2.221M	$1.658M
YoY Change	591.26%	85.06%	-24.65%
Accrued Expenses	$6.496M	$6.548M	$4.442M
YoY Change	36.13%	23.54%	-9.35%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$17.28M	$13.24M	$7.957M
YoY Change	189.27%	106.95%	9.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$781.0K	$803.6K	$779.7K
YoY Change	-12.64%	-19.64%	-29.12%
Total Long-Term Liabilities	$781.0K	$803.6K	$779.7K
YoY Change	-12.64%	-19.64%	-29.12%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.28M	$13.24M	$7.957M
Total Long-Term Liabilities	$781.0K	$803.6K	$779.7K
Total Liabilities	$18.06M	$14.05M	$8.737M
YoY Change	162.98%	-11.09%	-47.68%
SHAREHOLDERS EQUITY
Retained Earnings	$135.7M	$124.6M	$116.2M
YoY Change	29.32%
Common Stock	$81.84M	$81.20M	$80.66M
YoY Change	5.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$210.8M	$199.8M	$190.6M
YoY Change
Total Liabilities & Shareholders Equity	$235.7M	$222.9M	$208.0M
YoY Change	22.27%	20.14%	16.14%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2015 Q2
OPERATING ACTIVITIES
Net Income	$11.04M	$8.380M	$7.820M
YoY Change	41.27%	35.8%	-15.93%
Depreciation, Depletion And Amortization	$980.0K	$970.0K	$920.0K
YoY Change	-13.27%	-19.83%	-21.37%
Cash From Operating Activities	$16.12M	$8.910M	$10.90M
YoY Change	9.21%	20.73%	157.08%
INVESTING ACTIVITIES
Capital Expenditures	-$7.200M	-$900.0K	-$870.0K
YoY Change	1042.86%	275.0%	117.5%
Acquisitions
YoY Change
Other Investing Activities	-$5.740M	-$3.490M	-$6.020M
YoY Change	-143.32%	-82.55%
Cash From Investing Activities	-$12.94M	-$4.390M	-$6.890M
YoY Change	-202.54%	-78.31%	1622.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-880.0K	50.00K	0.000
YoY Change	-183.02%	-200.0%	-100.0%
NET CHANGE
Cash From Operating Activities	16.12M	8.910M	10.90M
Cash From Investing Activities	-12.94M	-4.390M	-6.890M
Cash From Financing Activities	-880.0K	50.00K	0.000
Net Change In Cash	2.300M	4.570M	4.010M
YoY Change	-91.91%	-135.4%	50.75%
FREE CASH FLOW
Cash From Operating Activities	$16.12M	$8.910M	$10.90M
Capital Expenditures	-$7.200M	-$900.0K	-$870.0K
Free Cash Flow	$23.32M	$9.810M	$11.77M
YoY Change	51.53%	28.74%	153.66%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1100000
CY2016Q4	anik	Accrued Clinical Trial Costs Current AccruedClinicalTrialCostsCurrent	227000
CY2015Q4	anik	Accrued Clinical Trial Costs Current AccruedClinicalTrialCostsCurrent	252000
CY2016Q4	anik	Accrued Research Grants Current AccruedResearchGrantsCurrent	463000
CY2015Q4	anik	Accrued Research Grants Current AccruedResearchGrantsCurrent	381000
CY2016Q4	anik	Accumulated Currency Translation Adjustment AccumulatedCurrencyTranslationAdjustment	5497000
CY2016	anik	Allowance For Doubtful Accounts Receivable Translation Adjustments AllowanceForDoubtfulAccountsReceivableTranslationAdjustments	-9000
CY2015	anik	Allowance For Doubtful Accounts Receivable Translation Adjustments AllowanceForDoubtfulAccountsReceivableTranslationAdjustments	-15000
CY2014	anik	Allowance For Doubtful Accounts Receivable Translation Adjustments AllowanceForDoubtfulAccountsReceivableTranslationAdjustments	-69000
CY2016	anik	Buildtosuite Lease Agreement BuildtosuiteLeaseAgreement	1723000
CY2015	anik	Buildtosuite Lease Agreement BuildtosuiteLeaseAgreement	30000
CY2014	anik	Buildtosuite Lease Agreement BuildtosuiteLeaseAgreement
CY2016	anik	Deferred Income Tax Expense Benefit Foreign And Domestic Net DeferredIncomeTaxExpenseBenefitForeignAndDomesticNet	-226000
CY2015	anik	Deferred Income Tax Expense Benefit Foreign And Domestic Net DeferredIncomeTaxExpenseBenefitForeignAndDomesticNet	-960000
CY2014	anik	Deferred Income Tax Expense Benefit Foreign And Domestic Net DeferredIncomeTaxExpenseBenefitForeignAndDomesticNet	798000
CY2016Q4	anik	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	69000
CY2015Q4	anik	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	69000
CY2016	anik	Effective Income Tax Reconciliation Nondeductible Expenses Permanent Items Percent EffectiveIncomeTaxReconciliationNondeductibleExpensesPermanentItemsPercent	0.005
CY2015	anik	Effective Income Tax Reconciliation Nondeductible Expenses Permanent Items Percent EffectiveIncomeTaxReconciliationNondeductibleExpensesPermanentItemsPercent	-0.003
CY2015	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Vested In Period Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsVestedInPeriodFairValue	1100000
CY2016Q4	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Ppreciation Rights Vested And Expected To Vest Outstanding Aggregate Intrinsic Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockPpreciationRightsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	21.70
CY2014	anik	Effective Income Tax Reconciliation Nondeductible Expenses Permanent Items Percent EffectiveIncomeTaxReconciliationNondeductibleExpensesPermanentItemsPercent	0.001
CY2016Q4	anik	Operating Leases Future Minimum Payments Due In Five Years And Thereafter OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter	4759000
CY2016	anik	Percentage Of Net Revenue PercentageOfNetRevenue	1
CY2015	anik	Percentage Of Net Revenue PercentageOfNetRevenue	1
CY2014	anik	Percentage Of Net Revenue PercentageOfNetRevenue	1
CY2016	anik	Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriodTotalIntrinsicValue	2100000
CY2015	anik	Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriodTotalIntrinsicValue	3100000
CY2016Q4	anik	Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingIntrinsicValue	22300000
CY2015Q4	anik	Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingIntrinsicValue	15200000
CY2016	anik	Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingWeightedAverageRemainingContractualTerm	P6Y292D
CY2015Q4	anik	Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageExercisePrice	18.75
CY2014Q4	anik	Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageExercisePrice	14.85
CY2016Q4	anik	Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageExercisePrice	26.15
CY2016	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Exercises In Period SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriod	74815
CY2015	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Exercises In Period SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriod	106478
CY2016	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Exercises In Period Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriodWeightedAverageExercisePrice	15.46
CY2015	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Exercises In Period Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriodWeightedAverageExercisePrice	10.96
CY2016	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Expirations In Period SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExpirationsInPeriod	3310
CY2015	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Expirations In Period SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExpirationsInPeriod	8825
CY2016	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Expirations In Period Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExpirationsInPeriodWeightedAverageExercisePrice	11.37
CY2015	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Expirations In Period Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExpirationsInPeriodWeightedAverageExercisePrice	20.03
CY2016	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Forfeitures In Period SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsForfeituresInPeriod	58841
CY2015	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Forfeitures In Period SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsForfeituresInPeriod	85349
CY2016	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Forfeitures In Period Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsForfeituresInPeriodWeightedAverageExercisePrice	30.05
CY2015	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Forfeitures In Period Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsForfeituresInPeriodWeightedAverageExercisePrice	19.77
CY2016	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Grants In Period SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsGrantsInPeriod	354275
CY2015	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Grants In Period SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsGrantsInPeriod	111625
CY2016	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Grants In Period Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsGrantsInPeriodWeightedAverageExercisePrice	40.77
CY2015	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Grants In Period Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsGrantsInPeriodWeightedAverageExercisePrice	39.25
CY2015Q4	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Outstanding Number SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingNumber	762260
CY2014Q4	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Outstanding Number SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingNumber	851287
CY2016Q4	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Outstanding Number SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingNumber	979569
CY2016Q4	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Vested Aggregate Intrinsic Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsVestedAggregateIntrinsicValue	16700000
CY2015Q4	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Vested Aggregate Intrinsic Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsVestedAggregateIntrinsicValue	11600000
CY2016Q4	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Vested And Expected To Vest Outstanding Number SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsVestedAndExpectedToVestOutstandingNumber	903076
CY2016Q4	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Vested And Expected To Vest Outstanding Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	24.92
CY2016	anik	Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Vested In Period Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsVestedInPeriodFairValue	1300000
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1607000
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	167000
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	147000
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	593000
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2303000
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8302000
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	27598000
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21652000
CY2016Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent
CY2015Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	4198000
CY2016Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	6496000
CY2015Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	4778000
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6496000
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4778000
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	802000
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	210000
CY2016Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	231000
CY2015Q4	us-gaap	Accrued Rent Current AccruedRentCurrent
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	26777000
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	24540000
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-7317000
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6649000
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	61735000
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	81685000
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1607000
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2225000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3392000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	647000
CY2015	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	847000
CY2014	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	9626000
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3392000
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2225000
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	194000
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	194000
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	167000
CY2016	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	16000
CY2015	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	3000
CY2014	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	377000
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1100000
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	146000
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	150000
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3265000
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3635000
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3895000
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-70000
CY2014	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2100000
CY2016Q4	us-gaap	Assets Assets	240246000
CY2015Q4	us-gaap	Assets Assets	235748000
CY2016Q4	us-gaap	Assets Current AssetsCurrent	170440000
CY2015Q4	us-gaap	Assets Current AssetsCurrent	176433000
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	0
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax	0
CY2016	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1257000
CY2015	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1949000
CY2014	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	52000
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	104261000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	110707000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100156000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63333000
CY2016Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	69102000
CY2015Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	61635000
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-6446000
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	10551000
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	36823000
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14627000
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15037000
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14627000
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15037000
CY2016	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	302000
CY2015	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	249000
CY2014	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	192000
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	18549000
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	18456000
CY2014	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	22388000
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	31879000
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	28604000
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	35523000
CY2016	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Concentration of Credit Risk and Significant Customers</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Company has no significant off-balance sheet risks related to foreign exchange contracts, option contracts, or other foreign hedging arrangements. The Company’s cash equivalents and investments are held with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> major international financial institutions.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Company, by policy, routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited.</div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> DePuy Synthes Mitek Sports Medicine (“Mitek”), represented <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">66%</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60%,</div> respectively, of the Company’s accounts receivable balance, no other single customer accounted for more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> of accounts receivable in either period.</div></div></div>
CY2016	us-gaap	Concentration Risk Percentage1 ConcentrationRiskPercentage1	1
CY2015	us-gaap	Concentration Risk Percentage1 ConcentrationRiskPercentage1	1
CY2014	us-gaap	Concentration Risk Percentage1 ConcentrationRiskPercentage1	1
CY2016Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	22695000
CY2015Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	11274000
CY2016Q4	us-gaap	Construction Payable Current ConstructionPayableCurrent	804000
CY2015Q4	us-gaap	Construction Payable Current ConstructionPayableCurrent	415000
CY2016Q4	us-gaap	Cost Of Goods Sold CostOfGoodsSold	7539000
CY2016Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	4998000
CY2016Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	6065000
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5425000
CY2015Q4	us-gaap	Cost Of Goods Sold CostOfGoodsSold	6290000
CY2015Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5176000
CY2015Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	5274000
CY2015Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	4313000
CY2016	us-gaap	Cost Of Goods Sold CostOfGoodsSold	24027000
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	21053000
CY2014	us-gaap	Cost Of Goods Sold CostOfGoodsSold	20930000
CY2016	us-gaap	Costs And Expenses CostsAndExpenses	52772000
CY2015	us-gaap	Costs And Expenses CostsAndExpenses	44865000
CY2014	us-gaap	Costs And Expenses CostsAndExpenses	44148000
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	14982000
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	14572000
CY2014	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	18301000
CY2015Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	3738000
CY2016Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	6548000
CY2015Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	6775000
CY2016Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	8376000
CY2015Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	7466000
CY2016	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	600000
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-370000
CY2014	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1153000
CY2016	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-72000
CY2015	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-557000
CY2014	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-477000
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-65000
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-747000
CY2014	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	815000
CY2016Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	11308000
CY2015Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	11204000
CY2016Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6548000
CY2015Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6775000
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	48000
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	66000
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-84000
CY2015	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-33000
CY2014	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	122000
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4760000
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4429000
CY2016Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	640000
CY2015Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	547000
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	1253000
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	1567000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1882000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1043000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	308000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	510000
CY2016Q4	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	677000
CY2015Q4	us-gaap	Deferred Tax Assets Unrealized Currency Losses DeferredTaxAssetsUnrealizedCurrencyLosses	762000
CY2016Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	2932000
CY2015	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	400000
CY2014	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	400000
CY2016	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.05
CY2016	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1.4
CY2016	us-gaap	Depreciation Depreciation	2700000
CY2015	us-gaap	Depreciation Depreciation	2700000
CY2014	us-gaap	Depreciation Depreciation	2600000
CY2016	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3734000
CY2015	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3775000
CY2014	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4706000
CY2016Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.56
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.61
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.59
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.46
CY2015Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.74
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.56
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.52
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.24
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.22
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.06
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.61
CY2016Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.54
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.59
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.57
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.45
CY2015Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.72
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.55
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.51
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.23
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.15
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.01
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.51
CY2016	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-138000
CY2015	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-208000
CY2014	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-184000
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.36
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.363
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.377
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	0.029
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	0.029
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	0.017
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.001
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.002
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.045
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.048
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.049
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Investment EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment	0.001
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Investment EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment	0
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Investment EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment	0.001
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.009
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.004
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.007
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3089000
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3082000
CY2016	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	1200000
CY2015	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	1100000
CY2014	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	3100000
CY2016	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	647000
CY2015	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	847000
CY2014	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	9626000
CY2016	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	647000
CY2015	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	847000
CY2014	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	9626000
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	8380000
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	7820000
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	3516000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	12482000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	2800000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	900000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	900000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	900000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	900000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	900000
CY2016	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-300000
CY2015	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-400000
CY2014	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-600000
CY2016Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	1126000
CY2015Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	1240000
CY2016Q4	us-gaap	Goodwill Goodwill	7214000
CY2015Q4	us-gaap	Goodwill Goodwill	7482000
CY2014Q4	us-gaap	Goodwill Goodwill	8339000
CY2016	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-268000
CY2015	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-857000
CY2016Q4	us-gaap	Gross Profit GrossProfit	20757000
CY2016Q3	us-gaap	Gross Profit GrossProfit	20785000
CY2016Q2	us-gaap	Gross Profit GrossProfit	20510000
CY2016Q1	us-gaap	Gross Profit GrossProfit	16853000
CY2015Q4	us-gaap	Gross Profit GrossProfit	19317000
CY2015Q3	us-gaap	Gross Profit GrossProfit	18500000
CY2015Q2	us-gaap	Gross Profit GrossProfit	17624000
CY2015Q1	us-gaap	Gross Profit GrossProfit	11202000
CY2016	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill
CY2015	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	697000
CY2014	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	50181000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	48608000
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	63232000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	50870000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	48254000
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	61505000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	689000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-354000
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1727000
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	18323000
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17496000
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	23186000
CY2016	us-gaap	Income Taxes Paid IncomeTaxesPaid	22826000
CY2015	us-gaap	Income Taxes Paid IncomeTaxesPaid	12724000
CY2014	us-gaap	Income Taxes Paid IncomeTaxesPaid	13778000
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5059000
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5625000
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-750000
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6201000
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4996000
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-898000
CY2016	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-3552000
CY2015	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	5484000
CY2014	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	8436000
CY2016	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1566000
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-199000
CY2014	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1189000
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-50000
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-15000
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2014000
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1738000
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2939000
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1974000
CY2016	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	66000
CY2015	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-94000
CY2014	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-213000
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	898000
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-89000
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-585000
CY2016Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	28206000
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	10227000
CY2015Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	11656000
CY2016	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	263000
CY2015	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	120000
CY2014	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	58000
CY2016Q4	us-gaap	Inventory Adjustments InventoryAdjustments	900000
CY2015Q4	us-gaap	Inventory Adjustments InventoryAdjustments	900000
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4540000
CY2015Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3502000
CY2016Q4	us-gaap	Inventory Net InventoryNet	15983000
CY2015Q4	us-gaap	Inventory Net InventoryNet	14938000
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5884000
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5780000
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	5559000
CY2015Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	5656000
CY2016	us-gaap	Inventory Write Down InventoryWriteDown	654000
CY2015	us-gaap	Inventory Write Down InventoryWriteDown	210000
CY2014	us-gaap	Inventory Write Down InventoryWriteDown	378000
CY2016	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1300000
CY2015	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1300000
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1400000
CY2016Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	27796000
CY2015Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	27622000
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	240246000
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	235748000
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8799000
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	17278000
CY2016Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	27456000
CY2015Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	24512000
CY2016Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	20500000
CY2015Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	27751000
CY2015	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation
CY2016	us-gaap	Nature Of Operations NatureOfOperations	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div> Nature of Business</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. The Company has over <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> decades of global expertise developing, manufacturing, and commercializing products based on the Company’s proprietary HA technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">The Company is subject to risks common to companies in the biotechnology and medical device industries including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with FDA and foreign regulations and approval requirements, as well as the ability to grow the Company’s business through appropriate commercial strategies.</div></div>
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-23346000
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1921000
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5332000
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6763000
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-30226000
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8303000
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	23801000
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	39064000
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	39978000
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	8085000
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	8952000
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	8615000
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	6895000
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	11042000
CY2014	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	6349000
CY2016	us-gaap	Net Income Loss NetIncomeLoss	32547000
CY2015	us-gaap	Net Income Loss NetIncomeLoss	30758000
CY2014	us-gaap	Net Income Loss NetIncomeLoss	38319000
CY2016	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	50607000
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	48134000
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	61447000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	11837000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1454000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1888000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1858000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1878000
CY2016Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	5200000
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	880000
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	438000
CY2016	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-668000
CY2015	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2154000
CY2014	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2796000
CY2016	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-700000
CY2015	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2200000
CY2014	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2800000
CY2014	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2796000
CY2015	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2154000
CY2016	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-668000
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2078000
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	781000
CY2015	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0
CY2016	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0
CY2016	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	25000000
CY2015	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock
CY2014	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock
CY2016	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation
CY2016	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	39249000
CY2015	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	45251000
CY2014	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	26750000
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14014000
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9225000
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1553000
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1250000
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1250000
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2098000
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1385000
CY2016	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	46500000
CY2015Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	14961000
CY2015	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	24250000
CY2014	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	20000000
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1007000
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1074000
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2055000
CY2015Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	0
CY2016Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	0
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	79073000
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	64648000
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	52296000
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	40108000
CY2016	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	52000
CY2015	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	38000
CY2014	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10732000
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8987000
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8144000
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	168209000
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	135662000
CY2015	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	5303000
CY2015Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	22898000
CY2014	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	30121000
CY2016	us-gaap	Revenue Recognition Sales Of Goods RevenueRecognitionSalesOfGoods	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Product Revenue</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><div style="display: inline; background-color: white">Revenues from product sales are recognized when title and risk of loss have passed to the customer, which is typically upon shipment to the customer. Amounts billed or collected prior to recognition of revenue are classified as deferred revenue. When determining whether risk of loss has transferred to customers on product sales, or if the sales price is fixed or determinable, the Company evaluates both the contractual terms and conditions of its distribution and supply agreements as well as its business practices. </div></div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><div style="display: inline; background-color: white"></div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><div style="display: inline; background-color: white">Product revenue also includes royalties. Royalty revenue is based on distributors’ sales and recognized in the same period distributors record their sale of products manufactured by the Company. On a quarterly basis the Company records royalty revenue based upon sales provided to it by its distributor customers. </div></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><div style="display: inline; background-color: white"></div></div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><div style="display: inline; background-color: white">Pursuant to the Health Care and Education Reconciliation Act of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010,</div> in conjunction with the Patient Protection and Affordable Care Act, a medical device excise tax (“MDET”) became effective on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2013</div> for sales of certain medical devices. Some of the Company’s product sales are subject to the provisions of the MDET. The Company has elected to recognize any amounts related to the MDET under the gross method as allowed under ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">605</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">45.</div> For the periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014,</div> amounts included in revenues and costs of goods sold for the MDET were immaterial. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015,</div> President Obama signed the Consolidated Appropriations Act of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> which suspends the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.3</div> percent MDET beginning on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> with the suspension ending on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div></div></div></div></div>
CY2016	us-gaap	Revenue Recognition Services Licensing Fees RevenueRecognitionServicesLicensingFees	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"><div style="display: inline; font-style: italic;">Licensing, Milestone and Contract Revenue</div></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0">Licensing, milestone and contract revenue consist of revenue recognized on initial and milestone payments, as well as contractual amounts received from partners. The Company’s business strategy includes entering into collaborative license, development, and/or supply agreements with partners for the development and commercialization of the Company’s products. Under the milestone method, the Company recognizes a consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"></div> <div style=" font-size: 10pt; margin: 0pt 0"> </div> <table style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 0.25in"></td> <td style="width: 0.25in"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div></td> <td>The consideration is commensurate with either the entity’s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone,</td> </tr> </table> <div style=" margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"> </div> <table style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 0.25in"></td> <td style="width: 0.25in"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div></td> <td>The consideration relates solely to past performance, and</td> </tr> </table> <div style=" margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"> </div> <table style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 0.25in"></td> <td style="width: 0.25in"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.</div></td> <td>The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.</td> </tr> </table> <div style=" margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"> </div> <div style=" font-size: 10pt; text-indent: 0.25in; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity’s performance or on the occurrence of a specific outcome resulting from the entity’s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, and (iii) that would result in additional payments being due to the Company. Non substantive milestones are recognized when there are no further obligations by the Company.</div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"> </div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The terms of the agreements typically include non-refundable license fees, funding of research and development and payments based upon achievement of certain milestones. The Company adopted ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2009</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,</div> <div style="display: inline; font-style: italic;">Revenue Recognition</div> in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2011,</div> which amends ASC Subtopic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">605</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,</div> <div style="display: inline; font-style: italic;">Multiple Element Arrangements</div> (“ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">605</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25”)</div> to require the establishment of a selling price hierarchy for determining the allocable selling price of an item. Under ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">605</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,</div> as amended by ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2009</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,</div> in order to account for an element as a separate unit of accounting, the element must have objective and reliable evidence of selling price of the undelivered elements. In general, non-refundable up-front fees and milestone payments that do not relate to other elements are recognized as revenue over the term of the arrangement as the Company completes its performance obligations.</div></div></div>
CY2016Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	28296000
CY2016Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	25783000
CY2016Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	26575000
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	22278000
CY2015Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	25607000
CY2015Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	23676000
CY2015Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	15515000
CY2016	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	102932000
CY2015	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	87696000
CY2014	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	75474000
CY2016Q4	us-gaap	Sales Revenue Net SalesRevenueNet	28726000
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	25789000
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	26581000
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	22283000
CY2015Q4	us-gaap	Sales Revenue Net SalesRevenueNet	30894000
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	23681000
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	22904000
CY2015Q1	us-gaap	Sales Revenue Net SalesRevenueNet	15520000
CY2016	us-gaap	Sales Revenue Net SalesRevenueNet	103379000
CY2015	us-gaap	Sales Revenue Net SalesRevenueNet	92999000
CY2014	us-gaap	Sales Revenue Net SalesRevenueNet	105595000
CY2016	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	447000
CY2015Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	14905000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18013000
CY2015	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14825000
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15074000
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	3392000
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	2225000
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	1607000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	0.9
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y182D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y182D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
CY2014	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2055000
CY2015	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1074000
CY2016	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1007000
CY2014	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	6348000
CY2016	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	25000000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	222773000
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	210848000
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	135635000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	178098000
CY2016Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15077000
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-indent: -0.55in; margin: 0pt 0 0pt 0.55in"><div style="display: inline; font-style: italic;">Use of Estimates</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.55in"> </div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div></div></div>
CY2016	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	434000
CY2015	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	387000
CY2014	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	591000
CY2016Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14979000
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15111000
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15307000
CY2015Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15353000
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15316000
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15336000
CY2015Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15330000
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15116000
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15321000
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15269000
CY2016Q4	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	14538000
CY2016Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	14625000
CY2016Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	14679000
CY2016Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	14875000
CY2015Q4	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	14965000
CY2015Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	14967000
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14682000
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14934000
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14678000

Files In Submission

Name	View Source	Status
0001171843-17-001121-index-headers.html	Edgar Link	pending
0001171843-17-001121-index.html	Edgar Link	pending
0001171843-17-001121.txt	Edgar Link	pending
0001171843-17-001121-xbrl.zip	Edgar Link	pending
anik-20161231.xml	Edgar Link	completed
anik-20161231.xsd	Edgar Link	pending
anik-20161231_cal.xml	Edgar Link	unprocessable
anik-20161231_def.xml	Edgar Link	unprocessable
anik-20161231_lab.xml	Edgar Link	unprocessable
anik-20161231_pre.xml	Edgar Link	unprocessable
exh_101a.htm	Edgar Link	pending
exh_103a.htm	Edgar Link	pending
exh_106a.htm	Edgar Link	pending
exh_211.htm	Edgar Link	pending
exh_231.htm	Edgar Link	pending
exh_311.htm	Edgar Link	pending
exh_312.htm	Edgar Link	pending
exh_321.htm	Edgar Link	pending
f10k_022417p.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
graph.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ANIK
Anika Therapeutics, Inc. Stock $anik

2015 Q4 Form 10-K Financial Statement

#000117184317001121 Filed on February 24, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIK Anika Therapeutics, Inc. Stock $anik

2015 Q4 Form 10-K Financial Statement

#000117184317001121 Filed on February 24, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIK
Anika Therapeutics, Inc. Stock $anik